Comparison of Lipid Profile in Patients With and Without Acute Myocardial Infarction

Comparison of Biochemical Parameters with Inhibition of Oxidative Stress in Myocardial Infarction Patients: In Vitro Study

Background: Myocardial infarction (MI) is the main cause of illness, mortality, and stress worldwide. Oxidative stress is the major cause of myocardium tissue damage associated with cell necrosis. Objectives: The current study was designed to compare biochemical parameters with in vitro antioxidant activity in MI patients. Methods: This observational cohort study was conducted on 53 MI patients, and the samples were collected on the basis of a non-random sampling technique from April 2022 to November 2022. Lipid profile (i.e., total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and triglycerides (TG)) and cardiac profile (i.e., troponin T, troponin I, creatine kinase MB (CK-MB), and creatine phosphokinase (CPK)) were measured for the confirmation of variation in biochemical parameters. Afterward, the inhibition of oxidative stress was analyzed through the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay on the serum samples of the patients. Results: Of 53 MI patients, 33 and 20 cases were male and female, respectively. Moreover, the correlation of the DPPH assay with TC, troponin T, and troponin I was determined by Pearson correlation. The correlation coefficients range from -1 to 1, indicating the strength and direction of the linear relationship between the markers. The concentrations of lipid profile (i.e., TC, TG, LDL, and VLDL) or cardiac profile (i.e., CK-MB, CPK, troponin T, and troponin I) were significantly elevated in all MI patients. However, the HDL level (P = 0.001) was decreased. Conclusions: According to obtained results, reactive oxygen species (ROS) might be the causative agent of MI. Therefore, if an antioxidant medication is used as administrative content, it would be helpful for the treatment of MI and a lead mark for pharmaceutical companies in drug designing for MI patients.

History of Pregnancy Loss as a Risk Factor for Myocardial Infarction

Introduction

There are few cardiovascular risk factors that are unique to females, such as after menopause, lipid profiles change unfavorably. Another risk factor that might be associated with an increased risk of cardiovascular diseases in women is the incidence of miscarriages and abortions. In this study, we will determine the association between the previous history of pregnancy loss and myocardial infarction (MI).

Methods

This case-control study was conducted from December 2019 to January 2021. We enrolled 600 female patients with a confirmed diagnosis of MI from the outpatient department (OPD) of the cardiology and internal medicine unit of a tertiary care hospital in Pakistan. Another 600 female participants without the diagnosis of MI were enrolled from the OPD as the control group. Participants were asked about the history of pregnancy, including the number of miscarriages, abortions, and stillbirths.

Results

Participants with myocardial infarction had experienced greater than one miscarriage compared to participants without MI (25.1% vs. 13.6%; p-value: <0.0001). Similarly, participants with MI had significantly more participants with stillbirth compared to participants without MI (12.0% vs. 6.66%; p-value: 0.0017).

Conclusion

Pregnancy loss is associated with MI in the future. Women with a history of pregnancy loss must undergo regular cardiovascular screening to protect themselves from cardiovascular events.

Two RECK Splice Variants (Long and Short) Are Differentially Expressed in Patients with Stable and Unstable Coronary Artery Disease: A Pilot Study

Primary prevention is crucial for coronary heart disease (CAD) and the identification of new reliable biomarkers might help risk stratification or predict adverse coronary events. Alternative splicing (AS) is a less investigated genetic factors implicated in CAD etiology. We performed an RNA-seq study on PBMCs from CAD patients and control subjects (CTR) and observed 113 differentially regulated AS events (24 up and 89 downregulated) in 86 genes. The RECK (Reversion-inducing-cysteine-rich protein with Kazal motifs) gene was further analyzed in a larger case study (24 CTR subjects, 72 CAD and 32 AMI patients) for its Splicing-Index FC (FC = −2.64; p = 0.0217), the AS event involving an exon (exon 18), and its role in vascular inflammation and remodeling. We observed a significant downregulation of Long RECK splice variant (containing exon 18) in PBMCs of AMI compared to CTR subjects (FC = −3.3; p < 0.005). Interestingly, the Short RECK splice variant (lacking exon 18) was under-expressed in AMI compared to both CTR (FC = −4.5; p < 0.0001) and CAD patients (FC = −4.2; p < 0.0001). A ROC curve, constructed combining Long and Short RECK expression data, shows an AUC = 0.81 (p < 0.001) to distinguish AMI from stable CAD patients. A significant negative correlation between Long RECK and triglycerides in CTR group and a positive correlation in the AMI group was found. The combined evaluation of Long and Short RECK expression levels is a potential genomic biomarker for the discrimination of AMI from CAD patients. Our results underline the relevance of deeper studies on the expression of these two splice variants to elucidate their functional role in CAD development and progression.